BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 26971341)

  • 21. Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.
    Channual S; Tan N; Siripongsakun S; Lassman C; Lu DS; Raman SS
    AJR Am J Roentgenol; 2015 Sep; 205(3):546-53. PubMed ID: 26295640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.
    Sugimoto K; Moriyasu F; Shiraishi J; Saito K; Taira J; Saguchi T; Imai Y
    Eur Radiol; 2012 Jun; 22(6):1205-13. PubMed ID: 22270142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity.
    Wu JW; Yu YC; Qu XL; Zhang Y; Gao H
    World J Gastroenterol; 2018 Jan; 24(3):415-423. PubMed ID: 29391764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images.
    Kim KA; Kim MJ; Jeon HM; Kim KS; Choi JS; Ahn SH; Cha SJ; Chung YE
    J Magn Reson Imaging; 2012 Mar; 35(3):629-34. PubMed ID: 22069244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic capability of gadoxetate disodium-enhanced liver MRI for diagnosis of hepatocellular carcinoma: comparison with multi-detector CT.
    Toyota N; Nakamura Y; Hieda M; Akiyama N; Terada H; Matsuura N; Nishiki M; Kono H; Kohno H; Irei T; Yoshikawa Y; Kuraoka K; Taniyama K; Awai K
    Hiroshima J Med Sci; 2013 Sep; 62(3):55-61. PubMed ID: 24279123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.
    Brunsing RL; Chen DH; Schlein A; Wolfson T; Gamst A; Mamidipalli A; Vietti Violi N; Marks RM; Taouli B; Loomba R; Kono Y; Sirlin CB
    Radiol Imaging Cancer; 2019 Nov; 1(2):e190010. PubMed ID: 33778680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution.
    Well L; Rausch VH; Adam G; Henes FO; Bannas P
    Rofo; 2017 Jul; 189(7):651-660. PubMed ID: 28445909
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening.
    Tillman BG; Gorman JD; Hru JM; Lee MH; King MC; Sirlin CB; Marks RM
    Clin Radiol; 2018 May; 73(5):485-493. PubMed ID: 29246586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.
    Goshima S; Kanematsu M; Kondo H; Watanabe H; Kawada H; Moriyama N; Bae KT
    AJR Am J Roentgenol; 2013 Sep; 201(3):578-82. PubMed ID: 23971449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI.
    Kumada T; Toyoda H; Tada T; Sone Y; Fujimori M; Ogawa S; Ishikawa T
    AJR Am J Roentgenol; 2011 Jul; 197(1):58-63. PubMed ID: 21701011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS).
    Chernyak V; Fowler KJ; Heiken JP; Sirlin CB
    J Magn Reson Imaging; 2019 May; 49(5):1236-1252. PubMed ID: 30609194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinction Between Hepatocellular Carcinoma and Hypervascular Liver Metastases in Non-cirrhotic Patients Using Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging.
    Ichikawa S; Morisaka H; Omiya Y; Onishi H
    Can Assoc Radiol J; 2022 Nov; 73(4):639-646. PubMed ID: 35341349
    [No Abstract]   [Full Text] [Related]  

  • 36. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.
    Galia M; Agnello F; Sparacia G; Matranga D; Albano D; Midiri M; Lagalla R
    Radiol Med; 2018 Jul; 123(7):489-497. PubMed ID: 29546493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
    Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
    AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma.
    Kunishi Y; Numata K; Morimoto M; Okada M; Kaneko T; Maeda S; Tanaka K
    AJR Am J Roentgenol; 2012 Jan; 198(1):106-14. PubMed ID: 22194485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.
    Choi SH; Byun JH; Kim SY; Lee SJ; Won HJ; Shin YM; Kim PN
    Invest Radiol; 2016 Aug; 51(8):483-90. PubMed ID: 26885632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.
    Orlacchio A; Chegai F; Fabiano S; Merolla S; Funel V; Di Giuliano F; Manuelli M; Tisone G; Francioso S; Angelico M; Palmieri G; Simonetti G
    Radiol Med; 2016 Jul; 121(7):588-96. PubMed ID: 27100719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.